Editorial Accompanying Blood Cover Story Features Promise Of Dexpramipexole In Eosinophil-Associated Diseases

We’re in touch to share an editorial published in the current edition of the journal Blood concerning our lead drug candidate. Entitled “Dexpramipexole: a new antieosinophil drug?,” the editorial summarizes recent Phase 2 studies of dexpramipexole in eosinophil-associated diseases, including the trial in hypereosinophilic syndrome (HES) separately reported on the cover of the August 2, 2018, edition of Blood by our collaborators at the National Institutes of Health.

The editorial, by world eosinophilic disease expert Dr. Gerald J. Gleich of the University of Utah School of Medicine, terms dexpramipexole “very promising,” noting that “the results in patients with durable and sustained responses are impressive and suggest that dexpramipexole could be an effective treatment of patients with eosinophil-related diseases.”

Taken together, results from the HES trial and a separate Phase 2 trial of dexpramipexole in chronic rhinosinusitis with nasal polyps “set the stage for Phase 3 clinical trials in patients with common eosinophil-related diseases,” the editorial says. Observing that long-term glucocorticoid therapy and associated adverse effects remain the mainstay of treatment in eosinophil-associated diseases, the editorial notes, “These early results encourage belief that this drug could herald a welcome change.”

A full copy of the Blood editorial is available at http://www.bloodjournal.org/content/132/5/461

This communication contains “forward-looking statements,” including statements relating to Knopp’s plans regarding research and clinical development programs for dexpramipexole. All forward-looking statements are based on current assumptions and expectations and involve risks, uncertainties, and other important factors, specifically including the uncertainties inherent in clinical trials and research and development programs, the availability of funding to support continued research and studies, and the availability of strategic alliances, as well as additional factors that may cause Knopp’s actual results to differ from expectations. There can be no assurance that dexpramipexole will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the product.